CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
- COVID-19 Phase 2 clinical trial fully enrolled
- Study compares mono- and bivalent vaccine candidates against licensed comparator COVID-19 vaccine
- First participant dosed in seasonal flu Phase 2 part of combined Phase 1/2 study
- Study compares a potentially differentiated, multivalent vaccine candidate with broad antigen coverage against licensed comparator vaccine
CureVac N.V. (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced solid progress in its clinical vaccine development programs in COVID-19 and seasonal flu, conducted in collaboration with GSK.